Celea Therapeutics has initiated its global Phase 3 SURPASS-IPF trial, dosing the first patient in a study evaluating deupirfenidone for idiopathic pulmonary fibrosis (IPF). This significant step follows the company's recently completed $180 million financing, enabling the advancement of a potential new standard of care. The trial is notably the first industry-sponsored Phase 3 study in IPF designed to demonstrate superiority over an existing approved therapy.
Advancing a New Standard of Care
Sven Dethlefs, CEO of Celea, highlighted the company's rapid execution in moving from financing to patient dosing. He emphasized that the trial aims to show deupirfenidone can achieve superior efficacy, a level previously thought possible only with combination therapies. The goal is to deliver a differentiated treatment option that maintains a favorable tolerability profile for patients with this devastating disease.
A Patient-Centric Trial Design
The pivotal SURPASS-IPF trial is a global, randomized, double-blind study comparing deupirfenidone directly against the approved antifibrotic, pirfenidone. It will enroll approximately 1,100 adults with IPF across more than 30 countries over a 52-week period. The primary endpoint will measure the change from baseline in absolute forced vital capacity (FVC), a key indicator of lung function.
A key feature of the trial is its patient-centric approach, which forgoes a placebo arm to ensure every participant receives active treatment. Dr. Rafael Lupercio, an investigator in the trial, noted that this design is a crucial consideration for individuals with a progressive illness like IPF. This head-to-head comparison is expected to generate highly meaningful evidence for both patients and the clinicians who care for them.
Building on Promising Phase 2 Data
The Phase 3 study builds upon strong results from the Phase 2b ELEVATE-IPF trial and its open-label extension. These earlier studies suggested deupirfenidone could substantially reduce lung function decline toward the rate seen in healthy aging adults. The SURPASS-IPF trial maintains continuity by using the same active comparator and dosing regimen evaluated in the Phase 2b program.
Deupirfenidone is an investigational, next-generation antifibrotic that is a deuterated form of pirfenidone. It was developed to overcome the efficacy and tolerability trade-offs that have historically limited the use of approved IPF therapies. By potentially offering a better-tolerated and more effective option, the drug aims to address a significant unmet need in the treatment landscape.
The Path Forward and Market Impact
Celea Therapeutics anticipates releasing topline results from the SURPASS-IPF trial in the second half of 2029. Based on feedback from the U.S. Food and Drug Administration, positive results from this single Phase 3 trial could be sufficient to support a registration filing. This milestone is celebrated by patient advocacy groups like the Pulmonary Fibrosis Foundation, which views the trial as a vital step toward more effective treatments.
The commencement of the SURPASS-IPF trial marks a critical juncture for Celea Therapeutics and the broader IPF community. By directly challenging an existing standard of care, the study has the potential to generate robust evidence needed to redefine treatment paradigms. If successful, deupirfenidone could offer new hope and improved outcomes for individuals living with this progressive and fatal lung disease.